Kalaris Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Kalaris Therapeutics Inc 's ROA in the second quarter of 2026?
Kalaris Therapeutics Inc recorded a cumulative net loss of $-44 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -38.28%.

However, within the Healthcare sector 510 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3844, from total ROA ranking in the first quarter of 2026 at 4510.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	62.7 %	6.51 %	4476.54 %	956.85 %	185.64 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-44	-44	-43	-52	-78
Return On Assets (TTM)	-38.28 %	-43.62 %	-43.69 %	-74.24 %	-151.27 %
KLRS's Total Ranking	# 3844	# 4510	# 4229	# 4444	# 4419
Total Assets (TTM) in million	151	110	122	80	93
Seq. Total Assets Change	37.28 %	-9.8 %	51.82 %	-13.46 %	-10.13 %
Seq. Net Income Change	-	-	-	-	-

KLRS's 5 Years Annual ROA >> Back to KLRS Management Effectiveness >> Compare KLRS ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 69
Sector	# 511
Overall	# 3795

Return On Assets Statistics
High	Average	Low
-3.66 %	-56.8 %	-95.98 %
(Dec 31 2020)		(Jun 30 2025)

Financial Statements
Kalaris Therapeutics Inc 's Assets	$ 151 million	KLRS's Balance sheet
Kalaris Therapeutics Inc 's Income	$ -12 million	Quarterly KLRS's Income Statement
KLRS's Income by Division		See KLRS's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	2.69 %	-37.16 %	-23.62 %	-4.23 %	-28.78 %
Total Assets in million	122	119	189	247	258
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-43	-59	-190	-169	-172
Annual Return On Assets	-35.68 %	-49.57 %	-100.95 %	-68.31 %	-66.68 %

KLRS's 5 Years Annual ROA >> Back to KLRS Management Effectiveness >> Compare KLRS ROA to its Competitors

More Return On Assets Ratios
KLRS's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
KLRS's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for KLRS's Competitors
Subscribers only: Roa for Kalaris Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for KLRS's Customers

You may also want to know
KLRS's Roi	KLRS's Inventory Turnover Ratio	KLRS's Growth Rates	KLRS's Dividend Comparisons
	KLRS's Profitability Ratios	KLRS's Asset Turnover Ratio	KLRS's Dividend Growth
KLRS's Roe	KLRS's Valuation Ratios	KLRS's Financial Strength Ratios	KLRS's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T15:16:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.